ArticleIJTLD open2026
Experiences from Ukraine in expanding TB infection diagnosis and treatment, including for drug-resistant TB.
Article in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUkraine faces intersecting epidemics of HIV and drug-resistant TB (DR-TB), with high risk of progression from TB infection to active disease. The Support TB Control Efforts in Ukraine project supported the National TB Program's efforts to operationalise World Health Organization recommendations on TB infection testing and TB preventive treatment (TPT) across 17 regions of Ukraine.
designIn September 2021, QuantiFERON-TB Gold Plus (QFT-Plus) testing was introduced through a public-private laboratory model. Eligible populations included TB contacts and other high-risk groups. Data on referrals, test outcomes, and TPT initiation were collected electronically and analysed descriptively.
resultsOut of 11,495 individuals referred for testing, 9,788 (85.2%) completed QFT-Plus testing, with adult TB contacts showing the highest positivity rate at 28.1%. Among 1,717 eligible for TPT, 1,512 (88.1%) started TPT, and this was 93.3% for drug-susceptible TB (DS-TB) contacts and 82.8% for DR-TB contacts. DS-TB contacts were offered shorter rifapentine-based regimens, while DR-TB contacts received levofloxacin. Implementation challenges were addressed through training and mentorship.
conclusionUkraine's implementation of QFT-Plus testing and shorter TPT regimens marks progress in broadening TB prevention efforts, particularly for DR-TB contacts. These initial results highlight that such approaches are feasible even in challenging, high-burden environments, offering insights for future expansion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.